STAT

Opinion: A dearth of physician innovators can derail new biomedical startups

As a physician shortage looms, few are talking about the lack of physician innovators and its effects on founding and growing biomedical startups.

Much has been made of the looming shortage of physicians. But there’s one place where the shortage is being felt acutely, is talked about even less, and the effects will ripple far into the future: the founding of new biomedical startups.

We live at a time when technology is dramatically transforming not just the field of biology but how biology-driven companies are built. It’s now entirely possible to create innovative and scalable new companies in the field with relatively modest initial funding. In other words, it’s salad days to be a bio startup, with so many new tools, data sources, and ideas at our disposal.

Yet there’s a moment of failure that crushes many such startups: when the new tool or technology connects with the real world of patients, physicians, medical records, hospitals, and insurers. That’s when a physician who can navigate the nuances

You’re reading a preview, subscribe to read more.

More from STAT

STAT1 min read
STAT+: Senate Drug Shortage Bill Would Pay Hospitals Bonuses For Good Contracting Practices
A bipartisan Senate bill takes a new approach to persistent drug shortages: have Medicare pay bonuses to hospitals and physicians for contracting that ensures a steady supply.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About GLP-1 Spending, Biosimilar Patient Costs, And More
Spending on GLP-1 drugs like Ozempic and Wegovy ballooned last year and they're set to cost the U.S. health care system and the federal government still more.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About FTC Fighting ‘Junk’ Patents, Pfizer Direct-to-consumer Plans, And More
The FTC expanded its campaign against pharmaceutical companies for filing what it calls “junk” patent listings for 20 different brand-name treatments.

Related Books & Audiobooks